Madison Muller

Amgen Inc. researchers have found a clue to one of the more puzzling questions in obesity drug development: How can blocking a hormone help people lose weight when activating the same hormone appears to work, too?

Merck & Co. was blocked from selling a new injectable version of its blockbuster cancer drug Keytruda in several European countries, dealing a setback to the drugmaker’s efforts to extend its most important franchise ahead of looming patent expirations.

Zealand Pharma A/S is teaming up with Generate Biomedicines Inc. in a billion-dollar deal to develop new obesity treatments using artificial intelligence, expanding the race for the next generation of weight-loss drugs.

The pharmaceutical industry is focused on getting AI to make us healthier.

Shares in Tempus AI fell after data on Moderna and Merck’s widely anticipated personalized melanoma vaccine disappointed Wall Street.

Bristol Myers Squibb Co. has reported a death in its clinical trials of an experimental cell therapy for autoimmune diseases, potentially adding to safety concerns about a promising new class of treatments.

An experimental drug from Merck & Co. helped women with advanced endometrial cancer live significantly longer than those receiving chemotherapy, bolstering the company’s ambitions for the novel treatment it is studying in a wide range of tumors.

Novo Nordisk A/S lost a bid in a US court to temporarily block Eli Lilly & Co. from using advertisements that claim its drugs are more powerful, a setback to Novo as it battles to regain a larger share of the obesity and diabetes drug markets.